FDA approves 1st drug shown to extend survival in rare disease

Advertisement

The FDA has approved Lembaz (adrabetadex) injection, the first treatment shown to help patients with infantile-onset Niemann-Pick disease type C live longer.

The drug is approved to reduce the risk of death in adult and pediatric patients who weigh at least 7 kilograms (about 15 pounds) and whose neurological symptoms began before age 6, according to a Nov. 17 FDA news release.

The FDA examined survival among 36 patients treated with Lembaz across three clinical studies and an expanded access program. Patients treated with Lembaz had a 55% lower risk of death compared with a matched external control group. Median survival was 8.5 years among treated patients compared with 4.9 years in the control group.

Lembaz is administered by a trained healthcare provider as an injection directly into the spinal canal every two weeks. The drug carries a boxed warning for hearing impairment, including permanent hearing loss.

The FDA granted approval to Mandos, a subsidiary of Beren Therapeutics.

Advertisement

Next Up in Pharmacy

Advertisement